November 2024

Corporate Overview

Innovating to Transform the Lives of Patients and Their Families

Jazz Pharmaceuticals

Caroline
Rylaze® patient diagnosed with ALL / LBL

Transforming Lives. Redefining Possibilities.

Caution Concerning Forward-Looking Statements

This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company's growth prospects and future financial and operating results, including the Company's 2024 financial guidance and the Company's expectations related thereto and anticipated catalysts; the Company's expectations for total revenue growth, sleep revenue growth, neuroscience revenue growth and oncology revenue growth and anticipated product sales; expectations of growth in net sales of Xywav, Epidiolex/Epidyolex and Rylaze combined; expectations with respect to royalties from Xyrem authorized generic products (AG products); the Company's expectations of growth of Xywav in IH and that Xywav will remain the oxybate of choice; the Company's development, regulatory and commercialization strategy; the Company's expectations with respect to potential corporate development; the advancement of pipeline programs and the timing of development activities, regulatory activities and submissions related thereto; the Company's expectations with respect to its products and product candidates and the potential of the Company's products and product candidates, including the potential of zanidatamab to be more than a two billion dollar market opportunity, and the potential regulatory path and commercial launch related thereto, including the potential launch in 2L BTC in 4Q24 and potential MAA approval; the Company's capital allocation and corporate development strategy; the potential successful future development, manufacturing, regulatory and commercialization activities; the Company's expectation of sustainable growth and meaningful value and the ability of near-term catalysts to drive substantial value creation; growing and diversifying the Company's revenue, investing in its pipeline of novel therapies, and delivering innovative therapies for patients and potential benefits of such therapies; the Company's ability to realize the commercial potential of its products and growth opportunities; planned or anticipated clinical trial events, including with respect to initiations, enrollment and data read-outs, and the anticipated timing thereof, including late-stage readouts of zanidatamab in GEA and suvecaltamide in Parkinson's disease tremor in 2025; the Company's clinical trials confirming clinical benefit or enabling regulatory submissions; planned or anticipated regulatory submissions and filings, and the anticipated timing thereof, including a planned sNDA for Zepzelca in 1L SCLC; potential regulatory approvals; and other statements that are not historical facts. These forward-looking statements are based on the Company's current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties.

Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with: maintaining or increasing sales of and revenue from Xywav, Rylaze, Epidiolex/Epidyolex and other products; Epidiolex achieving its blockbuster potential; the introduction of new products into the U.S. market that compete with, or otherwise disrupt the market for, the Company's oxybate products and other products and product candidates; effectively launching and commercializing the Company's other products and product candidates; the successful completion of development and regulatory activities with respect to the Company's product candidates; obtaining and maintaining adequate coverage and reimbursement for the Company's products; the time-consuming and uncertain regulatory approval process, including the risk that the Company's current and/or planned regulatory submissions may not be submitted, accepted or approved by applicable regulatory authorities in a timely manner or at all, including the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to the Company's business operations and financial results; geopolitical events, including the conflict between Russia and

Ukraine and related sanctions; macroeconomic conditions, including global financial markets, rising interest rates and inflation and recent and potential banking disruptions; regulatory initiatives and changes in tax laws; market volatility; protecting and enhancing the Company's intellectual property rights and the Company's commercial success being dependent upon the Company obtaining, maintaining and defending intellectual property protection and exclusivity for its products and product candidates; delays or problems in the supply or manufacture of the Company's products and product candidates; complying with applicable U.S. and non-U.S. regulatory requirements, including those governing the research, development, manufacturing and distribution of controlled substances; government investigations, legal proceedings and other actions; identifying and consummating corporate development transactions, financing these transactions and successfully integrating acquired product candidates, products and businesses; the Company's ability to realize the anticipated benefits of its collaborations and license agreements with third parties; the sufficiency of the Company's cash flows and capital resources; the Company's ability to achieve targeted or expected future financial performance and results and the uncertainty of future tax, accounting and other provisions and estimates; the Company's ability to meet its projected long-term goals and objectives in the time periods that the Company anticipates, or at all, and the inherent uncertainty and significant judgments and assumptions underlying the Company's long-term goals and objectives; fluctuations in the market price and trading volume of the Company's ordinary shares; restrictions on repurchases of capital stock; the timing and availability of alternative investment opportunities; and other risks and uncertainties affecting the Company, including those described from time to time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals' Securities and Exchange Commission filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2023 as supplemented by the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and future filings and reports by the Company. Other risks and uncertainties of which the Company is not currently aware may also affect the Company's forward- looking statements and may cause actual results and the timing of events to differ materially from those anticipated.

Transforming Lives. Redefining Possibilities.

Non-GAAP Financial Measures

To supplement Jazz Pharmaceuticals' financial results and guidance presented in accordance with U.S. generally accepted accounting principles (GAAP), the Company uses certain non-GAAP (also referred to as adjusted or non-GAAP adjusted) financial measures in this presentation. The Company presents non-GAAP adjusted net income (and the related per share measure) and certain line-item components. Non-GAAP adjusted net income (and the related per share measure) and its line-item components exclude from GAAP reported net income (and the related per share measure) and its line-item components certain items, as detailed in the reconciliation tables that follow in the Appendix hereto, and in the case of non-GAAP adjusted net income (and the related per share measure), adjust for the income tax effect of the non-GAAP adjustments. In this regard, the components of non-GAAP adjusted net income, including non-GAAP adjusted cost of product sales, SG&A (selling, general and administrative) expenses and R&D (research and development) expenses, are income statement line items prepared on the same basis as, and therefore components of, the overall non-GAAP adjusted net income measure. The Company also presents projected non-GAAP adjusted operating margin for 2024. Non-GAAP adjusted operating margin is calculated as total revenues less non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses divided by total revenues. Non-GAAP adjusted cost of product sales, SG&A expenses and R&D expenses exclude certain line-item components from GAAP reported cost of product sales, SG&A expenses and R&D expenses, as detailed in the non-GAAP adjusted operating margin reconciliation table that follows in the Appendix hereto. The Company also uses a non-GAAP net leverage ratio calculated as net adjusted debt (defined as total GAAP debt net of cash, cash equivalents and investments) divided by non-GAAP adjusted EBITDA for the most recent period of four consecutive completed fiscal quarters. EBITDA is defined as net income before income taxes, interest expense, depreciation and amortization. Adjusted EBITDA is defined as EBITDA further adjusted to exclude certain other charges and adjustments as detailed in the non-GAAP net leverage ratio reconciliation table that follows in the Appendix hereto and is calculated in accordance with the definition of Adjusted Consolidated EBITDA as set out in the Company's credit agreement entered into in May 2021 (the Credit Agreement).

The Company believes that each of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors and analysts and that each of these non-GAAP financial measures, when considered together with the Company's financial information prepared in accordance with GAAP, can enhance investors' and analysts' ability to meaningfully compare the Company's results from period to period and to its forward-looking guidance, and to identify operating trends in the Company's business and to understand the Company's ability to delever. In addition, these non-GAAP financial measures are regularly used by investors and analysts to model and track the Company's financial performance. The Company's management also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate the Company's business and to make operating decisions, and compensation of executives is based in part on certain of these non-GAAP financial measures. Because these non-GAAP financial measures are important internal measurements for the Company's management, the Company also believes that these non-GAAP financial measures are useful to investors and analysts since these measures allow for greater transparency with respect to key financial metrics the Company uses in assessing its own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures; should be read in conjunction with the Company's consolidated financial statements prepared in accordance with GAAP; have no standardized meaning prescribed by GAAP; and are not prepared under any comprehensive set of accounting rules or principles in the reconciliation tables that follow. In addition, from time to time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; and the Company has ceased, and may in the future cease, to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Likewise, the Company may determine to modify the nature of its adjustments to arrive at its non-GAAP financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used by the Company in this presentation and the accompanying tables have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies.

A Leading Growth-Oriented Biopharma Company

DUBLIN, IRELAND
Corporate Headquarters



Business Operations

Manufacturing Facilities

Growing Site

~2.8K
Employees Worldwide

>50%
R&D Employees Have Advanced Degree[1]

9
Medicines Commercialized[2]

>35
R&D Programs[3]

R&D = research and development. [1]>50% of Sr Director and above are PhD, PharmD or MDs; [2]https://www.jazzpharma.com/medicines/our-medicines/; [3]https://www.jazzpharma.com/science/pipeline/.

Jazz Pharmaceuticals

Our Purpose

is to innovate to transform the lives of patients and their families.

Who We Are

We are focused on developing life-changing medicines for people with serious diseases, often with limited or no therapeutic options, so they can live their lives more fully.

William
Xywav patient living with IH

Kasen and his mom Brittany
Epidiolex patient living with Dravet syndrome

IH = idiopathic hypersomnia.

Well-Positioned to Deliver Meaningful Value



Note: near-term growth drivers and pipeline catalysts are anticipated based on expectations for 2024; for further information, please see "Caution Concerning Forward-Looking Statements".
1L = first-line; GEA = gastroesophageal adenocarcinoma; TLR = top-line readout; YoY = Year-over-year, FY24 vs. FY23. [1]Key growth drivers consist of Xywav, Epidiolex, Rylaze.

Strong Track Record of Corporate Development Success

WELL-POSITIONED TO BE A PARTNER OF CHOICE

2005 — Orphan Medical
Acquisition
Established Jazz's sleep franchise

2012 — Azur Pharma
Merger
Established Jazz as global biopharmaceutical company

2012 — EUSA
Acquisition
Expanded oncology footprint, set the stage for Rylaze

2014 — Gentium
Acquisition
Expanded commercial portfolio in rare / orphan diseases

2016 — Celator
Acquisition
Strengthened hem/onc franchise

2019 — Zepzelca
Licensing Agreement
Set stage for future oncology growth in solid tumors, including zanidatamab

2021 — GW Pharma
Acquisition
Transformative transaction that rapidly diversified revenues

2022 — Zanidatamab
Licensing Agreement
$2B+ peak potential, multiple indications[1]

CONTINUE TO EVALUATE CORPORATE DEVELOPMENT OPPORTUNITIES TO DRIVE TOP-LINE REVENUE GROWTH AND DIVERSIFICATION

Note: Timeline shows select corporate development activity since 2005. Hem/onc = hematology & oncology. [1]Pending regulatory approval.

Strong Commercial Performance: Remain Focused on Growth

COMMERCIAL

Growing and diversified revenues

Sleep[1]
- **Xywav®** revenues **grew 17%** YoY
- Expect Xywav to **remain oxybate of choice**

Epidiolex®
- **Epidiolex** revenues **grew 18%** YoY
- Expect further **data generation** to support **additional growth**

Oncology
- **Oncology** revenues **grew 9%** YoY
- **Zepzelca®** revenues **grew 10%** YoY

PIPELINE

Zanidatamab 1L GEA is a late-stage near-term catalyst

Zanidatamab:
- **Ziihera® (zanidatamab-hrii)**[2] **approved** in 2L BTC under accelerated approval by the FDA
- 1L BTC **confirmatory trial ongoing**
- **Phase 3 EmpowHER-BC-303** breast cancer trial now **enrolling**
- Phase 3 GEA **top-line PFS readout estimated 2Q25**

Zepzelca:
- Reported **statistically significant OS and PFS from the IMforte trial**[3]
- Expect to **submit sNDA** for 1L ES-SCLC **in 1H25**

OPERATIONAL EXCELLENCE

Disciplined capital allocation enables investment in growth

Affirming 2024 total revenue and ANI guidance; raising EPS guidance:
- Total revenues **$4.0B – $4.1B**
- ANI[4] **$1.275B – $1.350B**
- Adjusted EPS[4] **$19.50 – $20.60**

Continued **top-line growth in 2024:**
- Total revenues **+6%** at guidance midpoint
- Expect **double-digit percent growth** of Xywav, Epidiolex, and Rylaze combined

Use financial strength to support growth
- Cash[5] at end of 3Q24: **$2.6B**
- Strong YTD operating cash flow of **~$1.0B**

1L = first line; 2L = second line; ANI = Adjusted net income; BTC = biliary tract cancer; EPS = earnings per share; ES = extensive stage; FDA = Food and Drug Administration; GEA = gastroesophageal adenocarcinoma; OS = overall survival; PFS = progression-free survival; SCLC = small stage lung cancer; sNDA = supplemental new drug application; YoY = Year-over-year, 3Q24 vs. 3Q23; YTD = year-to-date as of September 30, 2024. [1]Sleep therapeutic area consists of Xywav, Xyrem and high-sodium oxybate AG royalties; [2]https://pp.jazzpharma.com/pi/ziihera.en.USPI.pdf; [3]Study done in collaboration with F. Hoffmann-La Roche Ltd; [4]Non-GAAP adjusted net income (and the related per share measure) are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures" and reconciliation tables in the Appendix; [5]Cash, cash equivalents and investments.

Commercial

Growing and Diverse Revenue Streams

Jazz Pharmaceuticals

Xywav: Continued Growth Reinforces Durable Sleep Franchise

Diana
Xywav patient living with IH

KEY HIGHLIGHTS

Expect Xywav to remain the oxybate of choice

- **3Q24** Sleep[1] revenue of **$505 million**; increase of **~400 net patients exiting 3Q24** compared to 2Q24
- **First and only** FDA-approved therapy to treat IH
- **Field nurse educator program** helping patients navigate initiation of Xywav treatment
- Approved to treat the **full condition of IH**, including sleep inertia, which has significant impact on patients' quality of life and daily function

GROWTH OPPORTUNITIES

- Benefits of **reducing sodium intake** and an **individualized dosing regimen** continue to resonate with patients and HCPs
- **Expanded field force** to increase the breadth of IH prescribers

FDA = Food and Drug Administration; HCP = healthcare provider; IH = idiopathic hypersomnia. [1]Total revenue from Sleep includes Xywav, Xyrem and high-sodium oxybate AG royalty revenues.

Epidiolex: High Unmet Need in Pediatric Onset Epilepsy

Epidiolex®
Epidyolex®
cannabidiol
Oral solution

Ellamee
Epidiolex patient living with LGS

KEY HIGHLIGHTS

Broad spectrum efficacy through novel mechanism of action

- **>$2.7 billion**[1] in revenue since acquisition mid-2021
- **#1 branded epilepsy treatment**
- **High unmet need:**
  - Patients in the U.S. with: **DS ~10,000; LGS ~30,000-50,000; TSC ~40,000-50,000**

GROWTH OPPORTUNITIES

- Further data generation: Long-term Expanded Access Program study demonstrated Epidiolex was associated with a **sustained reduction in treatment-resistant, focal-onset seizures through ~2.5 years**[2]
- Education on **beyond-seizure benefits** utilizing data from the BECOME[3,4] survey
- **Nurse Navigator program** helps patients and families address medication-related topics
- Delivering programs and education to support **optimal dosing**
- Enhancing focus on additional opportunity in **adult patient setting**

DS = Dravet syndrome; LGS = Lennox-Gastaut syndrome; TSC = tuberous sclerosis complex. [1]Net product sales from May 2021 to September 30, 2024; [2]Park, Y., et al. Poster presented at: American Academy of Neurology, April 13-18, 2024; [3]Salazar TD, Berg A, Danese SR, et al. Poster presented at: American Epilepsy Society Annual Meeting; December 3-7, 2021; Chicago, IL; [4]Berg A, Perry MS, Salazar TD et al. Poster presented at: American Epilepsy Society Annual Meeting; December 3-7, 2021; Chicago, IL.

Rely on Rylaze: Successful Launch and Strong Demand

RYLAZE®
asparaginase erwinia chrysanthemi (recombinant)-rywn for injection 10mg/0.5mL per vial

ENRYLAZE

Emily
Rylaze patient diagnosed with ALL

KEY HIGHLIGHTS

Sustained asparaginase activity over the course of therapy essential to treatment success of ALL/LBL patients[1]

- **~$1.1 billion**[2] in revenue since launch in 2021
- **Only therapy available** to patients in the U.S. who have an HSR to *E. coli*-derived asparaginase

GROWTH OPPORTUNITIES

- **Continued opportunity for future growth in AYA setting**
- Switching to Rylaze at the **first sign of HSR** and due to other treatment-related issues
- **Temporary revenue impact** for Rylaze **limited to 3rd and 4th quarter** of this year and expected to **normalize by early 2025**
- Do not anticipate impact to overall Rylaze demand

ALL/LBL = acute lymphoblastic leukemia / lymphoblastic lymphoma; AYA = adolescents and young adults; HSR = hypersensitivity reaction; IM = intramuscular; M/W/F = Monday/Wednesday/Friday. [1]Salzer W, Bostrom B, Messinger Y, et al. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797-1806; [2]Net product sales from launch in July 2021 to September 30, 2024.

Zepzelca: #1 Treatment in 2L; Potential to Expand to 1L SCLC

ZEPZELCA® (lurbinectedin) for injection 4 mg

Donna
Zepzelca patient living with SCLC

KEY HIGHLIGHTS

Well-Established as 2L SCLC Treatment of Choice

- **>$1.1 billion**[1] in revenue since launch in mid-2020

GROWTH OPPORTUNITIES

Plan to submit sNDA for 1L ES-SCLC in 1H25

- Reported **statistically significant** and **clinically meaningful OS** and **PFS results from the Phase 3 trial** in combination with Tecentriq® (atezolizumab), conducted in collaboration with Roche[2]
- **Significant unmet need**: expected **median OS** for ES 1L SCLC patients is **~13 months**[3]
- Potential to **increase duration of response** with earlier line patients
- In the U.S., there are **~30,000 1L SCLC patients**, with **~27,000** currently treated in 1L and **~17,000** treated in 2L[4]

1L = first-line; 2L = second-line; ES = extensive-stage; OS = overall survival; PFS = progression-free survival; SCLC = small cell lung cancer; sNDA = supplemental New Drug Application. [1]Net product sales from launch in July 2020 to September 30, 2024; [2]F. Hoffmann-La Roche Ltd.; [3]Paz-Ares, L. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 Apr; 7(2):1004008; [4]Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Facts https://seer.cancer.gov/statfacts/html/lungb.html, accessed April 19, 2019, American Cancer Society, https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html, accessed April 12, 2019, Kantar Health Treatment Architecture SCLC July 2018, Jazz primary market research May 2019.

Pipeline

Multiple Near-term Catalysts Targeting Significant Market Opportunities

Jazz Pharmaceuticals

Robust and Productive Pipeline for Sustainable Growth

PRE-CLINICAL

Undisclosed targets
Oncology

CombiPlex
Oncology

KRAS inhibitor targets
Oncology

Undisclosed targets
Sleep

Undisclosed target
Epilepsy

Undisclosed targets
Other neuroscience[1]

PHASE 1

JZP815
Pan-Raf Inhibitor Program
Raf & Ras mutant tumors

Zanidatamab[2]
HER2-targeted bispecific antibody
Breast cancer and HER2-expressing cancers

JZP341
(Long-acting *Erwinia* asparaginase)
Solid tumors

JZP898 (WTX-613)[2]
Conditionally-activated IFNα

JZP351 (Vyxeos)
Low-intensity dosing for higher-risk MDS[3]

JZP324[4]
Oxybate extended-release formulation

JZP441 (DSP-0187)[2]
Orexin-2 receptor agonist

PHASE 2

Zanidatamab[2]
HER2-targeted bispecific antibody
- 2L monotherapy for BTC[5] (pivotal trial)
- Additional trials ongoing in BTC, GEA and CRC
- Multiple trials ongoing in breast cancer
- I-SPY2 Trial[6] in BC
- Monotherapy pan-tumor trial for previously treated HER2+ solid tumors[7]

JZP351
- HR-MDS (EMSCO)[8]
- Newly diagnosed older adults with HR-AML[8]

JZP351 + other approved therapies
- R/R AML or HMA Failure MDS[3]
- de novo or R/R AML[3]

Suvecaltamide (JZP385)
Parkinson's Disease Tremor

PHASE 3

Zanidatamab[2]
HER2-targeted bispecific antibody
- 1L zani + chemo ± tislelizumab for GEA[9] (pivotal trial)
- 1L confirmatory trial in HER2+ BTC[10]
- Zani + chemo vs. tras + chemo in HER2+ BC whose disease has progressed on previous T-DXd treatment[11]

Lurbinectedin (Zepzelca)[1]
1L treatment SCLC in combination with Tecentriq® (atezolizumab)

JZP351
- AML or HR-MDS >60yrs (AML18)[8]
- Newly diagnosed adults with standard- and HR-AML (AMLSG)[8]
- Newly diagnosed <22 yrs with AML (COG)[8]

Cannabidiol (Epidyolex)
LGS, DS, TSC in Japan

Oncology
Neuroscience
New Pipeline asset since 2018

Pipeline projects expanded >4x since 2018

1L = first line; 2L = second line; AML = acute myeloid leukemia; BC = breast cancer; BTC = biliary tract cancers; COG = Children's Oncology Group; CRC = colorectal cancer; DS = Dravet syndrome; EMSCO = European Myelodysplastic Neoplasms Cooperative Group; GEA = gastroesophageal adenocarcinoma; HER2 = human epidermal growth factor receptor 2; HMA = hypomethylating agents; HR = high-risk; IFNα = interferon alpha; LGS = Lennox-Gastaut syndrome; MDS = myelodysplastic syndromes; R/R = relapsing/refractory; SCLC = small cell lung cancer; SG = study group; T-DXd = trastuzumab deruxtecan; TSC = Tuberous sclerosis complex; zani = zanidatamab. [1]Partnered collaboration; [2]Acquired; [3]Jazz & MD Anderson Cancer Center collaboration study; [4]Planned; [5]HERIZON-BTC-01; [6]In collaboration with QuantumLeap Healthcare Collaborative; [7]DiscovHER-Pan-206; [8]Cooperative group study; [9]HERIZON-GEA-01; [10]HERIZON-BTC-302; [11]EMPOWHER-BC-303.

Key Pipeline Programs



1L = first line; 2L = second-line; BC = breast cancer; BLA = biologics license application; BTC = biliary tract cancer; DS = Dravet syndrome; ES = extensive-stage; FDA = Food and Drug Administration; GEA = gastroesophageal adenocarcinoma; HER2+ = human epidermal growth factor receptor 2 positive; LGS = Lennox-Gastaut syndrome; OS = overall survival; PFS = progression-free survival; SCLC = small cell lung cancer; sNDA = supplemental new drug application; T-DXd = trastuzumab deruxtecan; TSC = Tuberous sclerosis complex.

Zanidatamab

Jazz Pharmaceuticals

November 2024

Zanidatamab: Recent Data Continues to Strengthen Confidence

Updated Phase 2 1L GEA Data at ESMO[1]

- Treatment with zanidatamab plus chemotherapy in 1L GEA patients resulted in:
  - **cORR of 84%** [95% CI: 68.0, 94.0] with **one additional complete response** [4/37]
  - **mDOR of 18.7 months** [95% CI: 8.3-NE] with 10 patients having an ongoing response at the time of data cutoff
  - **mPFS increased to 15.2 months** [95% CI: 9.5, 33.4]
  - **24-month OS of 65%** [95% CI: 48.0, 78.0] with a **30-month OS of 59%** [95% CI: 41.0, 73.0]
- Data continues to support HERIZON-GEA-01 with **top-line data readout estimated 2Q25**

Kaplan-Meier Plot of PFS (A) and OS (B) in Patients with Centrally Confirmed HER2+ mGEA[1]



1L = first-line; ccHER2+ = central confirmed human epidermal growth factor receptor 2-positive; CI = confidence interval; cORR: confirmed overall response rate; ESMO = European Society for Medical Oncology; GEA = gastroesophageal adenocarcinoma; HER2 = human epidermal growth factor receptor 2; mDOR = median duration of response; mPFS = median progression-free survival; NE = not estimable; OS = overall survival. [1]Data as presented by Elimova et. al, ESMO 2024.

Zanidatamab: De-Risked Near-Term Opportunity with $2B+ Peak Potential

Significant regulatory progress:

- **Ziihera approved** for **2L BTC** by FDA in November 2024
- EMA **validated MAA;** potential **approval as early as 2Q25**

Biliary Tract Cancer

Approved under **accelerated approval** by FDA for 2L BTC

Launch in 2L BTC underway

1L BTC **confirmatory trial ongoing**

HERIZON-BTC-01: **Updated data at ASCO**

~12,000
BTC cases annually[2] in U.S., Europe[3] and Japan

Gastroesophageal Adenocarcinoma

Path to approval in 1L GEA with sBLA submission

HER2+/PD-L1 negative: opportunity to **address unmet need** and **replace trastuzumab**[1]

HER2+/PD-L1 positive: opportunity to replace trastuzumab as **HER2-targeted therapy of choice**[1]

Opportunity to **explore potential in neoadjuvant** populations[1]

~63,000
GEA cases annually[2] in U.S., Europe[3] and Japan

Breast Cancer

Expanded opportunity across lines of therapy[1]:
- Early lines of therapy (neoadjuvant)
- Post T-DXd (Ph3 EmpowHER trial)
- Novel combinations

Initiated Ph3 EmpowHER trial 2H24:
- Zanidatamab + chemo vs. tras + chemo in patients with HER2+ BC whose disease has progressed on or are intolerant to T-DXd treatment

Potential for **novel chemo-free regimen** for **HER2+/HR+** patients[1]

Ongoing trials in early breast cancer:
- I-SPY2 Trial[4]
- MD Anderson collaboration

~150,000
BC cases annually[5] in U.S., Europe[3] and Japan

Other HER2-Expressing Cancers

Broad potential beyond BTC, GEA, and BC in multiple HER2-expressing indications **based on compelling clinical activity from early trials**[6]:
- Colorectal
- NSCLC
- Ovarian
- Endometrial
- Pancreatic
- Bladder
- Salivary Gland
- Ampullary
- Other HER2-expressing solid tumors

Initiated Phase 2 DiscovHER-Pan-206
- Zanidatamab monotherapy in previously-treated patients with no available treatment options

Broad Potential
Beyond BTC, GEA, and BC

1L = first line; 2L = second line; ASCO = American Society of Clinical Oncology; BC = breast cancer; BLA = biologics license application; BTC = biliary tract cancer; EMA = European Medicines Agency; FDA = Food and Drug Administration; GEA = gastroesophageal adenocarcinoma; HER2 = human epidermal growth factor receptor 2; HR+ = hormone receptor positive; MAA = marketing authorization application; NSCLC = non-small cell lung cancer; PD-L1 = programmed cell death ligand 1; Ph 3 = Phase 3; sBLA = supplemental biologics license application; T-DXd = trastuzumab deruxtecan; tras = trastuzumab. [1]Pending regulatory approvals; [2]Incidence sources: Kantar reports, ToGA surveillance report; SEER, cancer.gov; ClearView Analysis; GLOBOCAN, Data on file; [3]Major markets, U.K, France, Germany, Spain, Italy; [4]NCT01042379, in collaboration with QuantumLeap Healthcare Collaborative; [5]Incidence source estimates derived from multiple sources: Decision Resources Group, Kantar Health, Jazz Market Research, data on file; [6]Funda Meric-Bernstam et al, Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study, The Lancet Oncology, Volume 23, Issue 12, 2022, Pages 1558-1570, ISSN 1470-2045, https://doi.org/10.1016/S1470-2045(22)00621-0.

Zanidatamab: Ongoing Phase 3 GEA Trial[1]

- Primary Endpoints: Progression-free survival (PFS) and overall survival (OS)
  - PFS as assessed by BICR as per RECISTv1.1
- Patients with locally advanced, recurrent or metastatic HER2-positive stomach and esophageal cancers, including GEJ
  - HER2+ defined as IHC3+ or IHC2+/ISH+ per central assessment
- **Top-line PFS data readout estimated 2Q25**



BICR = blinded independent central review; CAPOX = capecitabine plus oxaliplatin; FP = 5-fluorouracil plus cisplatin; GEA = gastroesophageal adenocarcinoma; GEJ = gastroesophageal junction; HER2 = human epidermal growth factor receptor 2; IHC = immunohistochemistry; ISH = in situ hybridization; RECIST = Response Evaluation Criteria in Solid Tumors. [1]HERIZON-GEA-01 trial.

Randomized Phase 3 Study of Zanidatamab + Chemotherapy in Post T-DXd Patients with HER2+ Advanced BC

- Patients with unresectable or metastatic HER2-positive[1] breast cancer who have progressed on, or are intolerant to, previous T-DXd treatment
- Primary Endpoints: Progression-free survival (PFS)
  - PFS as assessed by BICR as per RECISTv1.1
- Secondary Endpoints: OS, ORR, Safety
- **Initiated the Phase 3 EmpowHER-BC-303 trial in 3Q24**



BC = breast cancer; BICR = blinded independent central review; HER2 = human epidermal growth factor receptor 2; ORR = objective response rate; OS = overall survival; R = randomization; RECIST = Response Evaluation Criteria In Solid Tumors; T-DXd = trastuzumab deruxtecan, or Enhertu®. [1]Histologically confirmed HER2-positive breast cancer according to ASCO-CAP Guidelines as evaluated by a central laboratory

Zepzelca

Jazz Pharmaceuticals

November 2024

Zepzelca: Positive Top-Line Results from 1L ES-SCLC Phase 3 Trial

Unmet need



- Demonstrated **statistically significant** and **clinically meaningful improvement in OS** and **PFS** primary endpoints
- Potential to **delay disease progression** and **extend survival for patients**
- Plan to **submit sNDA** for **Zepzelca** in **1H25**
- **Significant unmet need**: expected median OS for ES 1L SCLC patients is **~13 months**[2]
- In the U.S., there are **~30,000 1L SCLC patients,** with **~27,000** currently **treated** in 1L and ~17,000 treated in 2L[1]; ~70% of 1L patients have extensive stage SCLC

Clinical Trial Design

Ph3 randomized, open-label trial of maintenance lurbinectedin in combination with atezolizumab compared to atezolizumab in participants with ES-SCLC.[3]

- **Primary endpoints:** PFS and OS
- **Secondary endpoints:** ORR, DOR, PFS and OS at specified times, Safety



1L = first-line; 2L = second-line; DOR = duration of response; ES = extensive stage; LS = limited stage; ORR = objective response rate; OS = overall survival; PFS = progression-free survival; RECIST = Response Evaluation Criteria In Solid Tumors; SCLC = small cell lung cancer; sNDA = supplemental New Drug Application. [1]Approximate U.S. SCLC patient numbers, sources: SEER Cancer Stat Facts https://seer.cancer.gov/statfacts/html/lungb.html, accessed April 19, 2019; American Cancer Society, https://www.cancer.org/cancer/small-cell-lung-cancer/about/what-is-small-cell-lung-cancer.html, accessed April 12, 2019; Kantar Health Treatment Architecture SCLC July 2018; Jazz primary market research May 2019; [2]Paz-Ares, L. et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022 Apr; 7(2):100408; [3]ClinicalTrials.gov identifier: NCT05091567. Updated March 28, 2023. Accessed April 27, 2023. https://clinicaltrials.gov/ct2/show/NCT05091567?term=imforte&draw=2&rank=1.

Suvecaltamide

Jazz Pharmaceuticals

November 2024

Suvecaltamide: Differentiated Mechanism of Action

Potency against all three Ca_V3[1] isoforms and >100-fold selectivity against other ion channel targets





- T-type calcium channels **regulate the balance of calcium ions**, acting as a **gatekeeper to help ions enter and leave the cell membrane**
- In pathological states (e.g. movement disorders), **increased activation of these channels** are thought to lead to the **excessive rhythmic signals that prompt tremor**[2,3]
- Hypothesize suvecaltamide **preferentially binds** to a **specific conformation of the channel** to **reduce and stabilize activity**

[1]There are three known types of T-type calcium channels, or Ca_V3, each associated with a specific α_1 subunit; [2]https://pubmed.ncbi.nlm.nih.gov/35240491/; [3]https://pubmed.ncbi.nlm.nih.gov/36738196/.

Suvecaltamide: Phase 2 Parkinson's Disease Tremor Trial

- Overall Design: 17-week, randomized, double-blind, placebo-controlled, flexible-dosing, parallel-group study
- Primary Endpoint: Change from baseline to week 17 on the Tremor Research Group Essential Tremor Rating Assessment Scale (TETRAS) Composite Outcome Score
- Estimated enrollment: 160 participants with moderate to severe residual tremor in adult participants with Parkinson's disease (PD). Inclusion criteria:
  - A score of > 21 on The Essential Tremor Assessment Rating Scale, Activities of Daily Living (TETRAS-ADL) subscale; and
  - Clinician Global Impression of Severity (CGI-S) rating of tremor severity of > 2 (at least moderate for participant's ability to function)
- **Top-line data expected 1Q25**



QD = Once daily dosing. [1]Diagnosis of clinically probable or clinically established Parkinson's disease (PD) meeting the Movement Disorder Society (MDS) 2015 criteria.

JZP815

Jazz Pharmaceuticals

November 2024

JZP815: Next-Generation, Pan-RAF Kinase Inhibitor

- JZP815 is a **highly selective** and **potent inhibitor** of activity against **all RAF protomers**
  - Sub-nanomolar activity against ARAF, BRAF and CRAF
- **Inhibits full spectrum** of RAF mutations and specific KRAS and NRAS driver mutations



Crystal structure of BRAF with ligand and JZP815





Source: Hauptschein, R, et al. JZP815, A Potent and Selective Pan-RAF Inhibitor, Demonstrates Efficacy in RAF and RAS Mutant Tumor Preclinical Models. AACR Annual Meeting 2022.

JZP815: Phase 1 First-in-Human Trial

- Open-label, non-randomized, multicenter trial in patients with advanced or metastatic solid tumors harboring alterations in the MAPK pathway
- Part A includes a dose exploration phase: Determine safety, MTD and/or RP2D and PK profile
- Part B will further investigate RP2D and examine antitumor activities across patient subsets based on mutation and/or tumor type
- Primary Endpoints: Dose-limiting toxicities, objective response rate per RECIST 1.1, duration of response and AEs



AEs = adverse events; BID = twice daily dosing; MAPK = mitogen-activated protein kinases; MTD = maximum tolerated dose; PK = pharmacokinetic; RECIST = Response Evaluation Criteria in Solid Tumors, version 1.1; RP2D = recommended phase 2 dose.

JZP898

Jazz Pharmaceuticals

November 2024

JZP898: Conditionally-Activated IFNα Therapy

Interferon Alpha (IFNα) Therapy

- High-dose **IFNα therapy approved for melanoma, lymphoma and leukemia**, but use **limited by systemic toxicity, modest efficacy**
- IFNα activates immune responses by engaging IFNα receptors (IFNARs) ubiquitously expressed on immune cells, or by inducing chemokines that attract myeloid and lymphoid cells to tumor site

JZP898[1] Differentiation

- Designed to be **first in-class, systemically delivered, conditionally activated IFNα molecule** for treatment of a wide variety of solid tumors
- Potential to **improve therapeutic index** of IFNα therapy by **minimizing severe toxicities associated with IFNα therapy** and **maximizing clinical benefit** when administered as monotherapy or in combination with immune checkpoint inhibitors
- Designed to systemically deliver a conditionally-activated IFNα therapy with **both IFNAR blockade** and potential for **full IFNα potency and function**



TME = tumor microenvironment. [1]WTX613, a conditionally activated IFNα INDUKINE™ molecule, induces anti-tumor immune responses resulting in strong tumor growth control in syngeneic mouse tumor models, E Tyagi et al, poster presented at SITC Annual Meeting, Nov. 10–14, 2021; Washington, D.C.

JZP898: Phase 1 First-in-Human Trial

- Open-label, non-randomized, multicenter trial in patients with advanced or metastatic solid tumors
- Part A1 includes a monotherapy dose exploration phase: Determine safety and MTD
- Part A2 includes combination dose exploration of JZP898 plus pembrolizumab: Determine RP2D
- Part B includes combination expansion using a basket design to evaluate clinical antitumor activity and safety of RP2D combination
- Primary Endpoints: Dose-limiting toxicities, objective response rate and AEs



AEs = adverse events; MTD = maximum tolerated dose; RP2D = recommended phase 2 dose.

Operational Excellence

Financial Strength and Discipline Enables Future Growth

Jazz Pharmaceuticals

Delivering Significant Value Through Strategic Capital Allocation

CAPITAL

~$1.0B
Cash from operations[1]

$2.6B
Cash, cash equivalents and investments[2]

$0.5B
Undrawn revolving credit facility[2]

DISCIPLINED DEPLOYMENT

COMMERCIAL GROWTH
New indications
Geographic expansion

PIPELINE EXPANSION
Advancing internal assets
Licensing new assets

CORPORATE DEVELOPMENT
Product acquisitions
Company acquisitions

STRATEGIC FINANCIAL POSITION
Enables investment in growth

STRATEGIC PRIORITIES

Diversified and growing revenue base

Differentiated pipeline to support future growth

Operational excellence to maximize value

[1]For the nine months ended September 30, 2024; [2]As of September 30, 2024

Continued Top-Line Growth

3Q24 Total Revenues



3Q24 Non-GAAP Adjusted ANI and EPS[1]

- **Xywav, Epidiolex,** and **Rylaze** revenues combined grew **14% YoY**
- **~$400M** cash generated from operations[4]
- **$2.6B** cash, cash equivalents and investments[5]
- **Disciplined capital allocation** underpins **bottom-line growth** and supports additional **investment in drivers of growth**

ANI = adjusted net income; EPS = earnings per share; YoY = year-over-year 3Q24 vs. 3Q23. [1]Non-GAAP adjusted net income (and the related per share measure) are non-GAAP financial measures. For further information see "Non-GAAP Financial Measures" and reconciliation table in the Appendix; [2]Neuroscience revenues include high-sodium oxybate authorized generic royalties; [3]In August 2023 and July 2024, we made irrevocable elections to fix the settlement method for exchange of the 2024 Notes and 2026 Notes, respectively, to a combination of cash and ordinary shares of the Company with a specified cash amount per $1,000 principal amount of the Exchangeable Senior Notes of $1,000. Excluding the dilutive impact of the Exchangeable Senior Notes, non-GAAP adjusted EPS for 3Q24 and 3Q23 would have been $6.74 and $5.34 per share, respectively, representing an increase in our non-GAAP adjusted EPS of 26%.; [4]For the quarter ended September 30, 2024; [5]Cash, cash equivalents and investments as of September 30, 2024.

2024 Revenue Guidance

Expect double-digit percentage growth of Xywav, Epidiolex, and Rylaze combined to drive total revenue growth in 2024

Neuroscience guidance includes:

- Growth expectations for Xywav in IH and Epidiolex/Epidyolex
- Continued decline in Xyrem net product sales
- Royalties on net sales of high-sodium AG exceeding $200M in 2024



AG = authorized generics; G = guidance; IH = idiopathic hypersomnia. [1]Includes high-sodium oxybate authorized generic royalties; [2]Guidance provided by Jazz Pharmaceuticals as of November 6, 2024.

2024 Non-GAAP Adjusted Guidance

Investing to Drive Growth:

- Disciplined capital allocation, including prioritized R&D investments and investing in commercial growth drivers, expected to drive sustainable long-term growth
- Guidance mid-points equate to adjusted operating margin[1,2] of ~43%

SG&A[2]

- Continued focus on operational excellence and operating margin
- Continue to support key growth drivers[3]



R&D[2]

- Investing in long-term and de-risked growth



ANI[2]

- Focused capital allocation enables investment in key growth drivers[3] and pipeline



At mid-point
Guidance range

ANI = non-GAAP adjusted net income; G = guidance; R&D = research and development; SG&A = selling, general and administrative. [1]Guidance provided by Jazz Pharmaceuticals as of November 6, 2024; [2]Non-GAAP Adjusted SG&A expenses, R&D expenses, net income and adjusted operating margin are non-GAAP financial measures; for further information see "Non-GAAP Financial Measures" and reconciliation tables in the Appendix; [3]Key growth drivers include Xywav, Epidiolex, and Rylaze.

Zanidatamab Provides Near-Term Catalysts

COMMERCIAL CATALYSTS

Epidiolex / Epidyolex
- Continued data generation

Xywav
- Meaningful growth opportunity in IH
- Expect to remain oxybate of choice in narcolepsy

Zanidatamab
- Ziihera approved in 2L BTC; launch underway

2024 / 2025

Commercial catalysts drive increased confidence in sustainable top-line revenue growth[1]

Zanidatamab provides near-term pipeline catalyst

Financial strength underpins ability to grow and execute on investment opportunities

PIPELINE CATALYSTS

Zanidatamab
- Potential EU approval as early as 2Q25
- Phase 3 EmpowHER late-line BC trial is enrolling
- Phase 3 1L GEA top-line data: estimated 2Q25

Zepzelca
- Expect to submit sNDA for 1L ES-SCLC in 1H25

1L = first line; 2L = second line; BC = breast cancer; BTC = biliary tract cancer; ES = extensive stage; GEA = gastroesophageal adenocarcinoma; IH = idiopathic hypersomnia; SCLC = small-cell lung cancer; sNDA = supplemental new drug application. [1]The Company expects top-line total revenue growth in 2024 relative to 2023 and over the two-year period ending in 2025.

Reconciliations

Jazz Pharmaceuticals

November 2024

Reconciliation of GAAP Reported Net Income and Diluted EPS to Non-GAAP Adjusted Net Income and Diluted EPS[1]

In thousands, except per share amounts (unaudited)	Three Months Ended September 30, 2024		Three Months Ended September 30, 2023	
	Net Income	Diluted EPS[2]	Net Income	Diluted EPS[2]
GAAP reported	**$215,055**	**$3.42**	**$146,820**	**$2.14**
Intangible asset amortization	157,457	2.49	154,883	2.17
Share-based compensation expense	59,760	0.95	56,115	0.79
Acquisition accounting inventory fair value step-up	35,034	0.55	30,822	0.43
Non-cash interest expense[3]	5,834	0.09	6,062	0.09
Income tax effect of above adjustments	(56,216)	(0.89)	(54,554)	(0.77)
Effect of assumed conversion of Exchangeable Senior Notes[2]	—	—	—	(0.01)
Non-GAAP adjusted[1]	$416,924	$6.61	$340,148	$4.84
Weighted-average ordinary shares used in diluted per share calculations – GAAP and non-GAAP[2]	**63,174**		**71,293**	

Note: Table may not foot due to rounding. EPS = earnings per share. [1]Non-GAAP adjusted net income (and the related per share measure) are non-GAAP financial measures; for further information see “Non-GAAP Financial Measures”; [2]Diluted EPS was calculated using the "if-converted" method in relation to the 1.50% exchangeable senior notes due 2024, or the 2024 Notes, and the 2.00% exchangeable senior notes due 2026, or the 2026 Notes, which we refer to collectively as the Exchangeable Senior Notes. In August 2023 and July 2024, we made irrevocable elections to net share settle the 2024 Notes and the 2026 Notes, respectively. As a result, the assumed issuance of ordinary shares upon exchange of the Exchangeable Senior Notes has only been included in the calculation of diluted net income per ordinary share, on a GAAP and on a non-GAAP adjusted basis, in each period up to the date each irrevocable election was made. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the three months ended September 30, 2024 included 1.3 million shares, related to the assumed conversion of the 2026 Notes and the associated interest expense, net of tax, add-back to GAAP reported net income of $1.0 million, and the associated interest expense, net of tax, add-back to non-GAAP adjusted net income of $0.9 million. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the three months ended September 30, 2023 included 7.6 million shares, related to the assumed conversion of the Exchangeable Senior Notes and the associated interest expense, net of tax, add-back to GAAP reported net income of $5.9 million, and the associated interest expense, net of tax, add-back to non-GAAP adjusted net income of $5.2 million. [3]Non-cash interest expense associated with debt issuance costs.

Reconciliation of GAAP Reported Net Income, Diluted EPS, SG&A Expenses and R&D Expenses to Non-GAAP Adjusted Net Income, Diluted EPS, SG&A Expenses and R&D Expenses[1]

In thousands, except per share amounts (unaudited)	Year ended December 31, 2023	
	Net Income	Diluted EPS[2]
GAAP reported	**$414,832**	**$6.10**
Intangible asset amortization	608,284	8.44
Share-based compensation expense	226,841	3.15
Acquisition accounting inventory fair value step-up	151,446	2.10
Other costs[3]	85,215	1.18
Non-cash interest expense[4]	22,378	0.31
Income tax effect of above adjustments	(213,172)	(2.95)
Effect of assumed conversion of Exchangeable Senior Notes[2]	—	(0.04)
Non-GAAP adjusted[1]	$1,295,824	$18.29
Weighted-average ordinary shares used in diluted per share calculations – GAAP and non-GAAP[2]	**72,066**	

In thousands (unaudited)	Year ended December 31, 2023	
	SG&A	R&D
GAAP reported	**$1,343,105**	**$849,658**
Share-based compensation expense	(146,942)	(64,847)
Other costs[3]	(85,215)	—
Non-GAAP adjusted[1]	$1,110,948	$784,811

Note: Table may not foot due to rounding. EPS = earnings per share; R&D = research and development; SG&A = selling, general and administrative. [1]Non-GAAP adjusted net income (and the related per share measure), SG&A expenses and R&D expenses are non-GAAP financial measures; for further information see “Non-GAAP Financial Measures”. [2]Diluted EPS was calculated using the "if-converted" method in relation to the 1.50% exchangeable senior notes due 2024, or the 2024 Notes, and the 2.00% exchangeable senior notes due 2026, or the 2026 Notes, which we refer to collectively as the Exchangeable Senior Notes. In August 2023, we made an irrevocable election to net share settle the 2024 Notes. As a result, the assumed issuance of ordinary shares upon exchange of the 2024 Notes has only been included in the calculation of diluted net income per ordinary share, on a GAAP and on a non-GAAP adjusted basis, in the year ended December 31, 2023 up to the date the irrevocable election was made. Net income per diluted share, on a GAAP and on a non-GAAP adjusted basis, for the year ended December 31, 2023, included 8.0 million shares, related to the assumed conversion of the Exchangeable Senior Notes and the associated interest expense, net of tax, add-back to GAAP reported and non-GAAP adjusted net income of $24.9 million and $22.2 million, respectively. [3]Includes costs related to the impairment of facility assets and program terminations; [4]Non-cash interest expense associated with debt issuance costs.

Reconciliation of GAAP to Non-GAAP Adjusted 2024 Guidance[1]

In millions, except per share amounts (unaudited)	2024 Guidance[1] Net Income	Diluted EPS[4]
GAAP	**$430 - $550** [2]	**$6.70 - $8.50**
Intangible asset amortization	605 - 645	9.10 - 9.85
Acquisition accounting inventory fair value step-up	125 - 145	1.90 - 2.20
Share-based compensation expense	235 - 255	3.55 - 3.90
Non-cash interest expense	20 - 30	0.30 - 0.45
Income tax effect of above adjustments	(210) - (220)	(3.15) - (3.35)
Non-GAAP adjusted[3,4]	$1,275 - $1,350 [2]	$19.50 - $20.60
Weighted-average ordinary shares used in per share calculations – GAAP and Non-GAAP	66	

In millions (unaudited)	2024 Guidance[1] SG&A	R&D
GAAP expenses	**$1,339 - $1,392** [5]	**$862 - $908** [6]
Share-based compensation expense	(149) - (162)	(72) - (78)
Non-GAAP adjusted expenses[3]	$1,190 - $1,230 [5]	$790 - $830 [6]

EPS = Earnings per Share; R&D = research and development; SG&A = selling, general and administrative. [1]Guidance provided by Jazz Pharmaceuticals as of November 6, 2024; [2]Using the projected GAAP and non-GAAP adjusted net income midpoint of $490M and $1,313M, respectively, we expect projected GAAP net income to increase 18% and non-GAAP adjusted net income to increase 1%, as compared to 2023 reported GAAP and non-GAAP adjusted net income of $415M and $1,296M, respectively; [3]Non-GAAP adjusted net income (and the related per share measure), SG&A expenses and R&D expenses are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures"; [4]Diluted EPS calculations for 2024 include an estimated 3.5 million shares related to the assumed conversion of the 2.00% exchangeable senior notes due 2026, or the 2026 Notes, and the associated interest expense, net of tax, add-back to net income of $11 million and $10 million, on a GAAP and on a non-GAAP adjusted basis, respectively, under the "if converted" method. In July 2024, we made the irrevocable election to net share settle the 2026 Notes. This election is expected to increase our full-year net income per diluted share by $0.15 to $0.25 per share, on a GAAP basis, and $0.70 to $0.75 per share, on a non-GAAP adjusted basis, as a result of the estimated decrease in the weighted-average outstanding shares of 2.9 million shares. [5]Using the projected GAAP and non-GAAP adjusted SG&A midpoint of $1,366M and $1,210M respectively, we expect projected GAAP and non-GAAP adjusted SG&A to increase 2% and 9%, respectively, as compared to 2023 reported GAAP and non-GAAP adjusted SG&A of $1,343M and $1,111M, respectively; [6]Using the projected GAAP and non-GAAP adjusted R&D midpoint of $885M and $810M, respectively, we expect projected GAAP and non-GAAP adjusted R&D to increase 4% and 3%, respectively, as compared to 2023 reported GAAP and non-GAAP adjusted R&D of $850M and $785M, respectively.

GAAP And Non-GAAP Adjusted Operating Margin[1,2] – FY 2024 Guidance[3]

The following table provides a reconciliation of the Company's projected 2024 GAAP cost of product sales, SG&A expenses and R&D expenses to non-GAAP adjusted cost of products sales, SG&A expenses and R&D expenses and the calculation of the Company's projected GAAP and non-GAAP adjusted operating margin:

Guidance in millions[3], except % (unaudited)	**GAAP**	**Non-GAAP adjusted**
Revenue	**$4,050**	$4,050
GAAP and non-GAAP adjusted cost of product sales, SG&A and R&D expenses[1]	**$2,684**	$2,303
GAAP and non-GAAP adjusted operating margin[1] %	**34 %**	43 %

Guidance in millions[3] (unaudited)	**Cost of product sales**	**SG&A**	**R&D**	**Total**
GAAP	**$433**	**$1,366**	**$885**	**$2,684**
Share-based compensation	(15)	(156)	(75)	(246)
Acquisition accounting inventory fair value step-up	(135)	—	—	(135)
Total non-GAAP adjusted[1]	$283	$1,210	$810	$2,303

Note: Table may not foot due to rounding. R&D = research and development; SG&A = selling, general and administrative.[1]Non-GAAP adjusted operating margin, non-GAAP adjusted cost of product sales, SG&A and R&D expenses are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures"; [2]Calculated at the midpoint; [3]Guidance provided by Jazz Pharmaceuticals as of November 6, 2024.

Reconciliation of GAAP Operating Margin to Non-GAAP Adjusted Operating Margin[1]

The following table provides a reconciliation of the Company's GAAP reported cost of product sales, SG&A expenses and R&D expenses to non-GAAP adjusted cost of products sales, SG&A expenses and R&D expenses and the calculation of the Company's GAAP and non-GAAP adjusted operating margin:

In millions, except % (unaudited)	Three Months Ended September 30, 2024		Nine Months Ended September 30, 2024	
	GAAP	Non-GAAP adjusted	GAAP	Non-GAAP adjusted
Revenue	**$1,055**	$1,055	**$2,981**	$2,981
GAAP reported and non-GAAP adjusted cost of product sales, SG&A and R&D expenses[1]	**$637**	$543	**$1,977**	$1,701
GAAP and non-GAAP adjusted operating margin[1] %	**40 %**	49 %	**34 %**	43 %

In millions (unaudited)	Cost of product sales	SG&A	R&D	Total	Cost of product sales	SG&A	R&D	Total
GAAP reported	**$112**	**$326**	**$200**	**$637**	**$317**	**$1,016**	**$644**	**$1,977**
Share-based compensation	(4)	(37)	(19)	(60)	(10)	(112)	(55)	(178)
Acquisition accounting inventory fair value step-up	(35)	—	—	(35)	(97)	—	—	(97)
Total non-GAAP adjusted[1]	$73	$289	$181	$543	$209	$904	$588	$1,701

Note: Table may not foot due to rounding. R&D = research and development; SG&A = selling, general and administrative. [1]Non-GAAP adjusted operating margin, adjusted cost of product sales, SG&A and R&D expenses are Non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures"

Non-GAAP Net Leverage Ratio based on non-GAAP Adjusted EBITDA[1]

Reconciliation of GAAP net income to Non-GAAP Adjusted EBITDA[1] (calculated in accordance with the Company's Credit Agreement) and the Calculation of Non-GAAP Net Leverage Ratio

In millions (unaudited)	LTM Ended 9/30/24
GAAP net income	**463**
Interest expense, net	257
Income tax benefit	(67)
Depreciation and amortization	651
Non-GAAP EBITDA	1,305
Share-based compensation expense	231
Acquisition accounting inventory fair value step-up	130
Restructuring and other costs	62
Upfront and milestone payments	28
Other	2
Non-GAAP Adjusted EBITDA[1]	1,756

In millions, except ratio (unaudited)	At 9/30/24
Calculation of Net Debt:	
Total GAAP debt	6,199
Cash, cash equivalents and investments	(2,618)
Net Debt	3,581
Calculation of non-GAAP Net Leverage Ratio[2]:	
Non-GAAP Net Leverage Ratio[2] based on non-GAAP Adjusted EBITDA[1]	2.0

Note: Table may not foot due to rounding. EBITDA = Earnings Before Interest, Income Tax, Depreciation and Amortization; LTM = Last Twelve Months. [1]Non-GAAP Adjusted EBITDA is calculated in accordance with the definition of Consolidated Adjusted EBITDA as set out in the Credit Agreement; [2]Non-GAAP Net Leverage Ratio and non-GAAP Adjusted EBITDA are non-GAAP financial measures; for further information, see "Non-GAAP Financial Measures".